App challenge focuses on pediatric patients

NewYork-Presbyterian is holding a hackathon and challenge for apps and games aimed at the pediatric patient population.

The InnovateNYP: Pediatric App Challenge is a 10-week event that begins the weekend of March 12 with a 30-hour hackathon aimed at developing tech innovations for pediatric care. After the ten weeks, finalist teams will demonstrate their innovations for an expert panel for the opportunity to receive feedback. Three winning teams will receive a total of $10,000 in prizes.

NewYork-Presbyterian is encouraging participants to work in groups of eight, and requires each team to use HL7's Fast Healthcare Interoperability Resources (FHIR) standards for data exchange between EHRs.

"Engaging the tech community represents a tremendous opportunity to develop new solutions in pediatrics," Daniel Barchi, CIO of NewYork-Presbyterian, said in a statement. "Following the success of our hackathon and challenge over the past two years, we felt it was again the right time to tap into innovative talent at the hospital and in the tech community. We look forward to seeing their creative ideas."

Participants may compete in the Appathon, Challenge or both. The competition is open to the general public, as well as New-York Presbyterian employees.

Learn more.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.